Press releaseGlobe Newswire
Fate Therapeutics
FATE · NASDAQ
$2.06+$0.20 (+10.75%)TodayMarket closed ·
Prev close $1.86
Latest news
- Press releaseGlobe Newswire
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
- Press releaseGlobe Newswire
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
- Press releaseGlobe Newswire
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
- Press releaseGlobe Newswire
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
- Press releaseGlobe Newswire
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
- News
Fate Therapeutics Highlights Initiation Of And Treatment Of First Patient In RECLAIM-LN, Phase 2 Potentially Registrational Clinical Trial Of FT819 In Patients With Refractory Moderate-To-Severe SLE With Lupus Nephritis
- Press releaseGlobe Newswire
Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
- Press releaseGlobe Newswire
Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
- NewsAvi Kapoor
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
- Press releaseGlobe Newswire
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
- Press releasePRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- Press releaseGlobe Newswire
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
- Press releaseGlobe Newswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
- Press releasePRNewswire
The $13 Million Company Teaching the Immune System to Hunt Cancer
- Press releasePRNewswire
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
- Press releasePRNewswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
- Press releasePRNewswire
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
- News
10 Health Care Stocks Whale Activity In Today's Session
- Press releasePRNewswire
Scalable Biotech Manufacturing Unlocks a $14B Market
- Press releaseGlobe Newswire
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed
- Press releasePRNewswire
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
- News
Fate Therapeutics Q4 Earnings Summary & Key Takeaways
- News
Earnings Summary: Fate Therapeutics Q4
- Press releasePRNewswire
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
- Press releaseGlobe Newswire
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
- Press releasePRNewswire
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
- News
4 Analysts Assess Fate Therapeutics: What You Need To Know
- Press releaseGlobe Newswire
Kaskela Law LLC Announces Shareholder Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Shareholders to Contact the Firm
- NewsAvi Kapoor
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.